Primary mediastinal large B-cell lymphoma

Optimal therapy and prognostic factor analysis in 141 consecutive patients treated at memorial Sloan Kettering from 1980 to 1999

Paul A. Hamlin, Carol S. Portlock, David J. Straus, Ariela Noy, Andrew Singer, Steven M. Horwitz, Owen A. Oconnor, Joachim Yahalom, Andrew D. Zelenetz, Craig Moskowitz

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Primary mediastinal large B-cell lymphoma (PMLBL) is a distinct clinicopathological entity with unclear prognostic factors and optimal treatment approach. To elucidate an optimal treatment and identify predictive factors, a retrospective analysis of 141 consecutive patients was undertaken. Patients received cyclophosphamide, hydroxydaunomycin, Oncovin, prednisone (CHOP)-like therapy, the non-Hodgkin lymphoma (NHL)-15 regimen or upfront autologous stem cell transplantation (ASCT) on Institutional Review Board approved trials or according to the institutional guidelines. Evaluation included lactate dehydrogenase, International Prognostic Index (IPI) assessment, computed tomography scan and gallium imaging. With a median follow-up of 10·9 years, event-free survival (EFS) and overall survival (OS) was 50% and 66% respectively. EFS/OS for CHOP/CHOP-like, NHL-15 and upfront ASCT was 34/51%, 60/84% and 60/78% respectively. CHOP/CHOP-like regimens had inferior EFS and OS versus NHL-15 or upfront ASCT (P < 0·001). A total of 23% of patients received radiotherapy. Multivariate analysis revealed the following outcome predictors: for EFS, greater than or equal to two extranodal sites and initial therapy received (NHL-15 or upfront ASCT); for OS, only initial therapy with NHL-15. We conclude: (i) dose-dense chemotherapy with NHL-15 may be superior to CHOP for PMLBL; (ii) The impact of consolidative radiotherapy requires randomised controlled trials; (iii) The age-adjusted IPI did not predict survival in this analysis; (iv) high-dose chemotherapy/ASCT should be reserved for upfront anthracycline-based therapy failure or in clinical trials for high-risk patients.

Original languageEnglish (US)
Pages (from-to)691-699
Number of pages9
JournalBritish Journal of Haematology
Volume130
Issue number5
DOIs
StatePublished - Sep 1 2005
Externally publishedYes

Fingerprint

Vincristine
B-Cell Lymphoma
Prednisone
Non-Hodgkin's Lymphoma
Cyclophosphamide
Statistical Factor Analysis
Stem Cell Transplantation
Disease-Free Survival
Survival
Radiotherapy
Therapeutics
Drug Therapy
Gallium
Research Ethics Committees
Anthracyclines
Survival Analysis
L-Lactate Dehydrogenase
Multivariate Analysis
Randomized Controlled Trials
Tomography

Keywords

  • Chemotherapy
  • Cyclophosphamide
  • Hydroxydaunomycin
  • Non-Hodgkin lymphoma
  • Oncovin
  • Prednisone
  • Risk factors
  • Transplant

ASJC Scopus subject areas

  • Hematology

Cite this

Primary mediastinal large B-cell lymphoma : Optimal therapy and prognostic factor analysis in 141 consecutive patients treated at memorial Sloan Kettering from 1980 to 1999. / Hamlin, Paul A.; Portlock, Carol S.; Straus, David J.; Noy, Ariela; Singer, Andrew; Horwitz, Steven M.; Oconnor, Owen A.; Yahalom, Joachim; Zelenetz, Andrew D.; Moskowitz, Craig.

In: British Journal of Haematology, Vol. 130, No. 5, 01.09.2005, p. 691-699.

Research output: Contribution to journalArticle

Hamlin, Paul A. ; Portlock, Carol S. ; Straus, David J. ; Noy, Ariela ; Singer, Andrew ; Horwitz, Steven M. ; Oconnor, Owen A. ; Yahalom, Joachim ; Zelenetz, Andrew D. ; Moskowitz, Craig. / Primary mediastinal large B-cell lymphoma : Optimal therapy and prognostic factor analysis in 141 consecutive patients treated at memorial Sloan Kettering from 1980 to 1999. In: British Journal of Haematology. 2005 ; Vol. 130, No. 5. pp. 691-699.
@article{4eff095344764ecdb81ce32172b667a1,
title = "Primary mediastinal large B-cell lymphoma: Optimal therapy and prognostic factor analysis in 141 consecutive patients treated at memorial Sloan Kettering from 1980 to 1999",
abstract = "Primary mediastinal large B-cell lymphoma (PMLBL) is a distinct clinicopathological entity with unclear prognostic factors and optimal treatment approach. To elucidate an optimal treatment and identify predictive factors, a retrospective analysis of 141 consecutive patients was undertaken. Patients received cyclophosphamide, hydroxydaunomycin, Oncovin, prednisone (CHOP)-like therapy, the non-Hodgkin lymphoma (NHL)-15 regimen or upfront autologous stem cell transplantation (ASCT) on Institutional Review Board approved trials or according to the institutional guidelines. Evaluation included lactate dehydrogenase, International Prognostic Index (IPI) assessment, computed tomography scan and gallium imaging. With a median follow-up of 10·9 years, event-free survival (EFS) and overall survival (OS) was 50{\%} and 66{\%} respectively. EFS/OS for CHOP/CHOP-like, NHL-15 and upfront ASCT was 34/51{\%}, 60/84{\%} and 60/78{\%} respectively. CHOP/CHOP-like regimens had inferior EFS and OS versus NHL-15 or upfront ASCT (P < 0·001). A total of 23{\%} of patients received radiotherapy. Multivariate analysis revealed the following outcome predictors: for EFS, greater than or equal to two extranodal sites and initial therapy received (NHL-15 or upfront ASCT); for OS, only initial therapy with NHL-15. We conclude: (i) dose-dense chemotherapy with NHL-15 may be superior to CHOP for PMLBL; (ii) The impact of consolidative radiotherapy requires randomised controlled trials; (iii) The age-adjusted IPI did not predict survival in this analysis; (iv) high-dose chemotherapy/ASCT should be reserved for upfront anthracycline-based therapy failure or in clinical trials for high-risk patients.",
keywords = "Chemotherapy, Cyclophosphamide, Hydroxydaunomycin, Non-Hodgkin lymphoma, Oncovin, Prednisone, Risk factors, Transplant",
author = "Hamlin, {Paul A.} and Portlock, {Carol S.} and Straus, {David J.} and Ariela Noy and Andrew Singer and Horwitz, {Steven M.} and Oconnor, {Owen A.} and Joachim Yahalom and Zelenetz, {Andrew D.} and Craig Moskowitz",
year = "2005",
month = "9",
day = "1",
doi = "10.1111/j.1365-2141.2005.05661.x",
language = "English (US)",
volume = "130",
pages = "691--699",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Primary mediastinal large B-cell lymphoma

T2 - Optimal therapy and prognostic factor analysis in 141 consecutive patients treated at memorial Sloan Kettering from 1980 to 1999

AU - Hamlin, Paul A.

AU - Portlock, Carol S.

AU - Straus, David J.

AU - Noy, Ariela

AU - Singer, Andrew

AU - Horwitz, Steven M.

AU - Oconnor, Owen A.

AU - Yahalom, Joachim

AU - Zelenetz, Andrew D.

AU - Moskowitz, Craig

PY - 2005/9/1

Y1 - 2005/9/1

N2 - Primary mediastinal large B-cell lymphoma (PMLBL) is a distinct clinicopathological entity with unclear prognostic factors and optimal treatment approach. To elucidate an optimal treatment and identify predictive factors, a retrospective analysis of 141 consecutive patients was undertaken. Patients received cyclophosphamide, hydroxydaunomycin, Oncovin, prednisone (CHOP)-like therapy, the non-Hodgkin lymphoma (NHL)-15 regimen or upfront autologous stem cell transplantation (ASCT) on Institutional Review Board approved trials or according to the institutional guidelines. Evaluation included lactate dehydrogenase, International Prognostic Index (IPI) assessment, computed tomography scan and gallium imaging. With a median follow-up of 10·9 years, event-free survival (EFS) and overall survival (OS) was 50% and 66% respectively. EFS/OS for CHOP/CHOP-like, NHL-15 and upfront ASCT was 34/51%, 60/84% and 60/78% respectively. CHOP/CHOP-like regimens had inferior EFS and OS versus NHL-15 or upfront ASCT (P < 0·001). A total of 23% of patients received radiotherapy. Multivariate analysis revealed the following outcome predictors: for EFS, greater than or equal to two extranodal sites and initial therapy received (NHL-15 or upfront ASCT); for OS, only initial therapy with NHL-15. We conclude: (i) dose-dense chemotherapy with NHL-15 may be superior to CHOP for PMLBL; (ii) The impact of consolidative radiotherapy requires randomised controlled trials; (iii) The age-adjusted IPI did not predict survival in this analysis; (iv) high-dose chemotherapy/ASCT should be reserved for upfront anthracycline-based therapy failure or in clinical trials for high-risk patients.

AB - Primary mediastinal large B-cell lymphoma (PMLBL) is a distinct clinicopathological entity with unclear prognostic factors and optimal treatment approach. To elucidate an optimal treatment and identify predictive factors, a retrospective analysis of 141 consecutive patients was undertaken. Patients received cyclophosphamide, hydroxydaunomycin, Oncovin, prednisone (CHOP)-like therapy, the non-Hodgkin lymphoma (NHL)-15 regimen or upfront autologous stem cell transplantation (ASCT) on Institutional Review Board approved trials or according to the institutional guidelines. Evaluation included lactate dehydrogenase, International Prognostic Index (IPI) assessment, computed tomography scan and gallium imaging. With a median follow-up of 10·9 years, event-free survival (EFS) and overall survival (OS) was 50% and 66% respectively. EFS/OS for CHOP/CHOP-like, NHL-15 and upfront ASCT was 34/51%, 60/84% and 60/78% respectively. CHOP/CHOP-like regimens had inferior EFS and OS versus NHL-15 or upfront ASCT (P < 0·001). A total of 23% of patients received radiotherapy. Multivariate analysis revealed the following outcome predictors: for EFS, greater than or equal to two extranodal sites and initial therapy received (NHL-15 or upfront ASCT); for OS, only initial therapy with NHL-15. We conclude: (i) dose-dense chemotherapy with NHL-15 may be superior to CHOP for PMLBL; (ii) The impact of consolidative radiotherapy requires randomised controlled trials; (iii) The age-adjusted IPI did not predict survival in this analysis; (iv) high-dose chemotherapy/ASCT should be reserved for upfront anthracycline-based therapy failure or in clinical trials for high-risk patients.

KW - Chemotherapy

KW - Cyclophosphamide

KW - Hydroxydaunomycin

KW - Non-Hodgkin lymphoma

KW - Oncovin

KW - Prednisone

KW - Risk factors

KW - Transplant

UR - http://www.scopus.com/inward/record.url?scp=27244432753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27244432753&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2005.05661.x

DO - 10.1111/j.1365-2141.2005.05661.x

M3 - Article

VL - 130

SP - 691

EP - 699

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -